
Male Hair Capsule
combines two medications that address different pathways involved in androgenetic hair loss.
$299.00 $150.00/mo; (3) month supply (1) bottle
An oral hair-loss treatment for men designed to reduce DHT and preserve scalp hair follicles.
Blood pressure & cardiovascular health: Oral minoxidil can affect blood pressure and cardiovascular function. Discuss treatment with your clinician if you have low blood pressure, dizziness or fainting, cardiovascular disease, rapid heart rate or palpitations, fluid retention or swelling, kidney disease, or take medications that lower blood pressure.
Sexual & reproductive effects: Dutasteride may cause decreased libido, erectile dysfunction, ejaculatory changes, and changes in semen volume. It may also affect semen parameters. Patients actively trying to conceive or with fertility concerns should discuss treatment with their clinician.
Pregnancy exposure: Women who are pregnant or may become pregnant should not handle leaking or damaged dutasteride-containing capsules because dutasteride can be absorbed through the skin and may pose a risk to a developing male fetus.
PSA testing: Dutasteride can lower PSA levels. Tell your healthcare provider that you are taking dutasteride so prostate screening results can be interpreted appropriately.
Blood donation: Follow clinician and blood-donation guidance regarding donation restrictions during treatment and after discontinuation.
Long half-life: Dutasteride has a long elimination half-life, meaning the medication and its biological effects can persist after treatment is stopped.
Potential side effects may include:
Individual response and tolerability may vary.
The formula targets male-pattern hair loss through two complementary mechanisms. Minoxidil supports follicular activity and the active hair-growth phase, while dutasteride reduces DHT production to address androgen signaling that contributes to follicular miniaturization in genetically susceptible men.
DHT, or dihydrotestosterone, is an androgen produced when 5-alpha-reductase converts testosterone into DHT. In genetically susceptible scalp follicles, DHT can contribute to progressive follicular miniaturization, causing hairs to become shorter and finer over time.
Minoxidil influences hair-follicle activity and the hair-growth cycle. It may help maintain follicles in the anagen, or active growth, phase, supporting increased hair density in responsive individuals.
Dutasteride inhibits type I and type II 5-alpha-reductase, the enzymes involved in converting testosterone into DHT. Reducing DHT can decrease androgen-related pressure on susceptible scalp follicles.
Hair grows slowly and follows a multi-stage growth cycle. Visible changes from hair-loss treatment generally require consistent use over time, and individual response varies.
Dutasteride can cause sexual side effects in some patients, including decreased libido, erectile dysfunction, and ejaculatory changes. It can also affect certain semen parameters. Patients who are actively trying to conceive or have fertility concerns should discuss treatment with their clinician.
Yes. Dutasteride can lower PSA levels, which can affect the interpretation of prostate screening results. Tell your healthcare provider you are taking dutasteride before PSA testing.
No. Male Hair Capsule is a compounded combination formulation and is not FDA-approved. Oral minoxidil and dutasteride have FDA-approved indications individually, but their use for hair loss as described here is off-label.
Male Hair Capsule is a compounded prescription formulation combining Minoxidil 5 mg + Dutasteride 2.5 mg.
The formula targets two major pathways involved in male-pattern hair loss: hair-follicle growth signaling and DHT-related follicular miniaturization.
Minoxidil supports follicular activity and the hair-growth cycle, while dutasteride reduces production of DHT, an androgen strongly associated with male-pattern hair loss in genetically susceptible men.
Oral minoxidil and dutasteride are used off-label for hair loss, and this compounded combination is not FDA-approved for hair loss.
All dosing should follow the instructions provided by the prescribing clinician.

combines two medications that address different pathways involved in androgenetic hair loss.

supports hair-follicle activity and may help maintain follicles in the active growth phase, supporting continued hair production and improved density in responsive individuals.

inhibits type I and type II 5-alpha-reductase, reducing the conversion of testosterone into DHT. Lowering DHT exposure may help slow progressive miniaturization and preserve susceptible scalp follicles.

Together, the two ingredients provide a dual-pathway approach: minoxidil supports active follicular growth while dutasteride addresses a primary hormonal driver of male-pattern hair loss.
Male-pattern hair loss is primarily influenced by genetic susceptibility and androgen signaling. However, hair loss can have other causes, and sudden, patchy, severe, or unexplained hair loss should be medically evaluated.
All dosing should follow the instructions provided by the prescribing clinician.
Male Hair Capsule combines minoxidil and dutasteride to target two distinct pathways potentially involved in male-pattern hair loss: follicular growth signaling and androgen-mediated follicular miniaturization. Minoxidil may support follicular activity and prolong the anagen growth phase, while dutasteride inhibits 5-alpha-reductase, reducing the conversion of testosterone to dihydrotestosterone (DHT). By reducing DHT signaling while supporting the hair-growth cycle, this combination may help support hair density, follicular function, and long-term hair maintenance.
